Study wrapper · #737
Mitochondria-derived peptides in liver disease: Emerging regulators of hepatic metabolism and therapeutic targets.
Editor's note
This review synthesises the role of mitochondrial-derived peptides, humanin, MOTS-c, and SHLPs, in liver homeostasis and disease. MOTS-c features substantially: the authors describe it activating AMPK, regulating nuclear gene expression, and suppressing fibrotic and inflammatory signalling in models of metabolic dysfunction-associated steatotic liver disease (MASLD) and fibrosis. As a review it aggregates preclinical mechanism rather than testing outcomes, and the human evidence base for MOTS-c in liver disease remains thin. There are no clinical efficacy data here. Publishable as orientation for readers tracking MOTS-c's hepatic biology, with the clear caveat that it summarises emerging preclinical signals, not established therapy.
Plain-language abstract
Mitochondria-derived peptides (MDPs) are small proteins made from mitochondrial DNA that help regulate metabolism and cell survival. This review focuses on their role in the liver. It covers humanin, MOTS-c, and a family called SHLPs, explaining how they help keep liver cells healthy by supporting mitochondrial function, reducing oxidative stress, and limiting cell death. MOTS-c gets significant attention: the authors describe how it activates an energy-sensing switch (AMPK), influences gene activity, and dials down scarring and inflammation signals in models of fatty liver disease and fibrosis. Because this is a review of laboratory and animal findings rather than a clinical trial, it does not show that MOTS-c helps people with liver disease; it maps out the emerging science. For readers, the useful takeaway is a sense of how MOTS-c might act in the liver and that this remains an early-stage, preclinical area needing human study.